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Abstract: Although early breast cancer (BC) is highly curable, advanced or metastatic disease 
poses numerous challenges in terms of medical management and treatment decisions and is 
associated with significantly worse prognosis. Among the new targeted agents, anticancer drugs 
exploiting the cell-cycle machinery have shown great potential in preclinical studies. CDK4/6 
inhibitors target the cyclin D/CDK/retinoblastoma signaling pathway, inducing cell-cycle 
arrest, reduced cell viability and tumor shrinking. As the cyclin D/CDK complex is activated 
downstream of estrogen signaling, the combination of CDK4/6 inhibitors with standard endo-
crine therapies represents a rational approach to elicit synergic antitumor activity in hormone 
receptor-positive BC. The results of clinical trials have indeed confirmed the superiority of 
the combination of CDK4/6 inhibitors plus endocrine therapies over endocrine therapy alone. 
Currently approved are three compounds that exhibit similar structural characteristics as well 
as biological and clinical activities. Abemaciclib is the latest CDK4/6 inhibitor approved by 
the US Food and Drug Administration (FDA) in view of the results of the MONARCH 1 and 
2 trials. Further trials are ongoing as other important questions await response. In this review, we 
focus on abemaciclib to examine preclinical and clinical results, describing current therapeutic 
indications, open questions and ongoing clinical trials.
Keywords: CDK4/6 inhibitor, abemaciclib, breast cancer, hormone receptor-positive BC, 
metastatic BC, mBC
Introduction
Breast cancer (BC) is the most common cancer in women worldwide,1 accounting 
for ~30% of all cancers, and the second cause of cancer-related death after lung cancer. 
The American Cancer Society estimated that 252,710 new cases will be diagnosed 
and 40,610 women will die of BC in the US in 2017.2
While the availability of new therapies and treatment combinations has drastically 
improved outcomes and early BC is highly curable, ~20% of women will experience 
local or distant recurrence at some point in time, even after 5–10 years from diagnosis,3,4 
mainly due to acquired pharmacological resistance. Prognosis for these patients is 
worse, and new approaches are needed.
Among novel possible therapeutic targets, proteins involved in the control of 
the cell-cycle machinery have recently attracted a lot of interest, as dysregula-
tion of cellular proliferation is recognized as one of the hallmarks of malignant 
transformation.5,6 Progression through the cell cycle is tightly regulated in mamma-
lian cells by a group of proteins called cyclins, which in turn pair with and activate 
serine–threonine kinases (cyclin-dependent kinases [CDKs]). Specific cyclin/CDK 
heterodimeric complexes regulate transition through the stages of the cell cycle acting 
as checkpoints. One of their targets, the retinoblastoma (Rb) protein, also represents 
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a critical checkpoint regulator in mammalian cells, directly 
controlling progression from Phase G1 to S,7 DNA synthesis 
and irreversible commitment to cellular division at the 
so-called “G1 restriction point”. When hypophosphorylated, 
Rb inhibits progression through the cell cycle by binding to 
and suppressing the activity of the E2F family of transcrip-
tion factors.8 The G1–S cyclin-dependent kinase 4 (CDK4) 
and cyclin-dependent kinase 6 (CDK6) in complexes with 
cyclin D first and the CDK2/cyclin E later promote phospho-
rylation of Rb, thus overriding Rb inhibition of proliferation 
and initiating cellular division (Figure 1).9
Alterations in the cyclin D/CDK/Rb pathway arise in 90% 
of cancers.10 In particular, multiple molecular aberrations 
result in disruption of this pathway in 50%–70% of BCs.11,12 
Overexpression of cyclin D1 is the most frequent alteration, 
found in ~50%–60% of BCs, in particular in luminal B and 
HER2-positive BCs.11,13 Loss of expression of the Rb protein 
occurs in 20%–30% of BCs, mainly in the triple-negative 
BC (TNBC) molecular subtype. Finally, loss of p16, an 
endogenous CDK4 and CDK6 inhibitor, occurs in ~50% of 
invasive BCs.13–15
Considering the relative frequency of genetic aberrations 
of cell-cycle-regulating proteins found in BC, the therapeutic 
potential of targeting this pathway became increasingly clear 
in the past 10 years.
The first generation of CDK4 and CDK6 inhibi-
tors (ie, flavopiridol) underwent clinical testing with 
generally disappointing results. In fact, due to the lack 
of selectivity for the target, these pan-CDK inhibitors 
showed an unfavorable safety profile, with a range of drug-
mediated, dose-limiting side effects.16–18 Moreover, the 
intravenous route and the schedule of administration added 
complexity to the treatment regimens impacting on patient 
compliance. Flavopiridol, the most studied compound of 
this group, showed scarce activity as a single agent and only 
moderate activity in combination with chemotherapy.18
The second generation of CDK inhibitors, even though 
designed to be more selective, was limited by severe 
toxicities. Dinaciclib induced severe adverse events in 60% 
and 74% of patients in a Phase I and a Phase II clinical trial, 
respectively, while its effectiveness remained limited.19,20
The next generation of CDK inhibitors, besides the 
advantage of the oral route of administration, showed a much 
higher selectivity, specifically targeting CDK4 and CDK6.21,22 
Three compounds, palbociclib (PD 0332991; Pfizer, Inc.), 
ribociclib (LEE011; Novartis International AG) and abe-
maciclib (LY2835219; Eli Lilly and Company), underwent 
preclinical and clinical testing and are currently approved 
for the treatment of advanced and/or metastatic hormone 
receptor-positive/HER2-neu-negative BC (HR+/HER2−).
This review focuses on abemaciclib in HR+/HER2− BC, 
examining preclinical and clinical results, current therapeutic 
indications and ongoing clinical trials.
Abemaciclib: mode of action and 
preclinical results
LY2835219 (abemaciclib) was identified via compound and 
biochemical screening by scientists at Eli Lilly and Company 
Research Laboratories and selected for its biological activ-
ity and highly selective inhibition of the complexes CDK4/
cyclin D1 (IC
50
 =2 nmol/L) and CDK6/cyclin D1 (IC
50
 
=10 nmol/L), with no activity against other CDK/cyclin 
complexes or cell-cycle-related kinases within the nanomolar 
ranges, except for inhibition of CDK9 at IC
50
 at least five 
times higher (Figure 2).23 The compound was shown to act 
as a competitive inhibitor of the ATP-binding domain of the 
CDK4 and CDK6 and to be 14 times more potent against 
CDK4 than against CDK6.24 In comparison to palbociclib 








Figure 1 Mode of action of CDK4/6 inhibitors.
Notes: Palbociclib, ribociclib and abemaciclib inhibit the complex CDK4/cyclin D1, 
responsible for the phosphorylation and inhibition of the Rb tumor-suppressor 
gene’s product. when Rb is phosphorylated, the cell proceeds from G1 to Phase S 












Figure 2 Chemical structure of LY2835219/abemaciclib.
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complex CDK4/cyclin D1, with IC
50
 values five times lower 
than those of the two other compounds (Table 1).
Inhibition of phosphorylation of Rb protein resulted in 
G1 cell-cycle arrest in both in vitro and in vivo experiments 
on multiple cancer cell lines from colorectal, lung, glioblas-
toma and blood cancers. When tested on tumor xenografts 
in nude mice, LY2835219 elicited potent dose-dependent 
antitumor activity, comparable to that of PD0332991 
(palbociclib), inducing ~70% of tumor volume regression, 
and was well tolerated when administered on a continuous 
schedule. The authors also tested the compound in vivo in 
combination with gemcitabine, reporting a synergic effect 
of the combination on Calu-6 lung subcutaneous xenografts 
and a greater antitumor activity in comparison to the single 
treatments in the absence of enhanced toxicity.23
Besides the cell-cycle dependent activity, Goel et al26 
recently showed that abemaciclib is able to boost antitumor 
immunity by potentiating tumor antigen presentation and 
selectively suppressing proliferation of regulatory T (T
reg
) 
cells at the same time. In this very elegant work, abemaciclib 
was shown to upregulate expression of type III interferons 
and interferon-stimulated genes/transcription factors, such 
as STAT1, STAT2, IRF2, IRF6, IRF9 and NLRC5, in the 
tumors of a transgenic mouse model of BC. At the same 
time, the CDK4/6 inhibitor reduced the number of T
reg
 cells 
in the spleen and lymph nodes of both tumor-bearing and 
tumor-free wild-type mice (tumor-independent effect). When 
these cells were isolated and cultured in vitro, addition of 
abemaciclib slowed down their proliferation without affect-
ing CD8+ or CD4+ T cells. The same effect was observed in 
vivo in abemaciclib-treated tumors.
Ultimately, all these effects induced cytotoxic T cell- 
mediated killing of tumor cells which, as suggested in the 
study, could be further increased with the addition of anti- 
immune checkpoint therapies. The authors were able to dem-
onstrate that the antitumor activity of abemaciclib is dependent 
on the presence of intratumoral cytotoxic T lymphocytes.
In addition, the authors confirmed previous reports’ 
finding that LY2835219/abemaciclib acts by promoting 
cellular senescence phenotypes in BC cells, as shown by the 
presence of marked hypermethylation and accumulation of 
endogenous beta-galactosidase.24,26
More specific to LY2835219 in comparison to other 
CDK4 and CDK6 inhibitors is the ability to cross the blood–
brain barrier, with concentrations of the drug in the cerebro-
spinal fluid comparable to the ones in plasma.27–31
Experiments in vitro and in vivo on mouse xenografts 
models of glioblastoma showed that palbociclib can also 
cross the blood–brain barrier,32 but subsequent clinical studies 
have provided inconsistent results.33
In view of these findings, abemaciclib is being tested 
in the clinic and holds promise in primary brain tumors 
(NCT03220646, NCT02981940) and in brain metastases from 
breast or other cancers (Bachelot et al. Poster presentation at 
2017 San Antonio Breast Cancer Symposium; December 6–9, 
2017; San Antonio, TX. Abstract P1-17-03).30,31
Abemaciclib in clinical trials
Phase i
Based on the very promising results obtained in preclinical 
studies, abemaciclib entered clinical development. In Phase I 
studies, abemaciclib, alone and in combination with ful-
vestrant or other antihormone therapies, showed favorable 
pharmacokinetic and toxicity profiles in patients with hormone-
positive metastatic breast cancer (mBC), with most common 
grade 3 treatment-related side effects being diarrhea, neutro-
penia, nausea and fatigue. No febrile neutropenia or grade 4 
events were reported.34–36 Single-agent abemaciclib was well 
tolerated when given on a continuous schedule to patients 
with different cancers, and fatigue was the dose-limiting side 
effect in a more recent Phase I study.30 In all the trials, the drug 
showed antitumor activity in multiple tumor types, including 
BC, and in often heavily pretreated patients, with an objective 
response rate (ORR) of 26% in hormone-refractory estrogen 
receptor positive (ER+) mBC when given as single therapy30 
and disease control rates ranging from 70% in all tumor types 
to 81% in HR+ patients.34 The most encouraging results were 
obtained in the group of HR+ mBC patients treated with the 
combination of abemaciclib and fulvestrant, which elicited 
62% of confirmed partial responses (PRs) in patients who 
had received on average four prior systemic therapies.35
Phase ii
These results prompted the launch of a Phase II trial, 
MONARCH 1, to evaluate the antitumor activity of abemaciclib 
Table 1 CDK4/6 inhibitors’ selectivity
Palbociclib Ribociclib Abemaciclib
iC50 for CDK/cyclin complexes (nmol/L)
CDK4/cyclin D1 11 10 2
CDK6/cyclin D1 16 39 10
CDK1/cyclin B .10,000 .10,000 1,627±666
CDK2/cyclin A/e .70,000 .10,000 504±298
CDK5/p25 .40,000 .10,000 355
CDK9/cyclin T1 NR NR 57±42
Notes: Data are presented as average of independent determinations ± SD. Data 
from Gelbert et al23 and Tripathy et al.25 For number of repeats and other information, 
please see cited references..
Abbreviation: NR, not reported.





as a single agent in patients with refractory HR+/HER2– 
mBC who received prior chemotherapy after progression 
on endocrine therapies.37 This single-arm study enrolled 132 
hormone receptor-positive mBC patients who had progressed 
on endocrine therapy and already received multiple systemic 
therapies (average of three prior systemic regimens). Abe-
maciclib was orally administered, at a dose of 200 mg twice 
daily, on a continuous schedule, until disease progression or 
unacceptable toxicity. The primary end point of the study was 
ORR, calculated as the total number of complete response 
(CR) or PR divided by the total number of patients; second-
ary end points were clinical benefit rate, progression-free 
survival (PFS) and overall survival (OS).
Worth noting was that 90.2% of patients had visceral 
disease and 50.8% had more than three sites of metastases.
Single-agent abemaciclib induced PRs (measured by 
RECIST criteria v 1.1) in 26 (19.7%) of the total 132 patients 
enrolled. No CRs were detected, with an ORR of 19.7% 
(95% CI: 13.3–27.5). The clinical benefit rate was 42.4%. 
Median PFS was 6 months (95% CI: 4.2–7.5), and median 
OS was 17.7 months (95% CI: 16–not reached). At the final 
analysis, at 18 months, median OS was 22.3 months (95% 
CI: 17.7–not reached).
Serious adverse events (SAEs) were reported in 32 
(24.2%) patients, and grade 5 events, all deemed not related 
to the drug, occurred in three patients. Diarrhea was the most 
frequent adverse event, reported by 119 (90.2%) patients, 
most often grade 1 (41.7%) or grade 2 (28.8%) and most 
frequently during the first cycle of treatment. Grade 3 diarrhea 
was observed in 26 (19.7%) patients. Duration of episodes 
was generally limited, and loperamide was administered 
in 60.6% of patients. The majority of patients did not need 
abemaciclib dose reduction or discontinuation (72.3%), 
and only one patient permanently ceased treatment because 
of this adverse event. Other common adverse events were 
fatigue, nausea and decreased appetite, in accordance with 
previous reports.
All grades neutropenia was observed in 87.7% of patients. 
Grade 3 neutropenia occurred in 22.3% of patients, whereas 
4.6% of patients had a grade 4 event. One patient had 
febrile neutropenia in the follow-up period and after discon-
tinuation of the drug, during successive chemotherapy.
A dose reduction of abemaciclib due to adverse events 
other than diarrhea was necessary in 65 (49.2%) patients.
Phase iii
The favorable pharmacokinetics and the strong evidence 
of an antitumor effect prompted the initiation of Phase III 
clinical trials.
MONARCH 2 compared the combination of abemaci-
clib and fulvestrant to fulvestrant alone in patients with 
HR+/HER2− advanced BC, which had progressed on endo-
crine therapy.38 In this international double-blind Phase III 
trial, 669 women were randomized to receive fulvestrant 
plus placebo or fulvestrant plus abemaciclib. Patients 
received abemaciclib or placebo twice daily on a continuous 
schedule of 28-day cycles. When the study began, patients 
in the abemaciclib arm were receiving 200 mg twice daily. 
After a safety data review and the analysis of dose-reduction 
rates among patients, the original dose was reduced to 150 mg 
for all patients, new and already enrolled. The trial’s primary 
end point was investigator-assessed PFS, and the secondary 
end points were OS, ORR and duration, clinical benefit 
rate, quality of life and safety.
The combination of abemaciclib and fulvestrant dem-
onstrated superiority to treatment with fulvestrant alone 
in this group of patients: median PFS in the combination 
group was 16.4 months in comparison to 9.3 months of the 
fulvestrant-alone group (hazard ratio [HR] 0.553; 95% CI: 
0449–0.681; p,0.001). ORR in patients with measurable 
disease was 48.1% (95% CI: 42.6–53.6) in the abemaciclib 
plus fulvestrant group versus 21.3% (95% CI: 15.1–27.6) 
in the fulvestrant-alone group (p,0.001). The median dura-
tion of response was not reached in the abemaciclib plus 
fulvestrant group at the time of the analysis. CR occurred 
in 11 (3.5%) patients with measurable disease. No CR was 
achieved in the fulvestrant-alone group.
The most common adverse events of any grade were 
diarrhea, neutropenia, nausea, fatigue and abdominal pain. 
Only 1.4% of the patients on abemaciclib experienced febrile 
neutropenia. Of these, one febrile neutropenia occurred 
53 days after discontinuation of investigational drug, when 
the patient had already started chemotherapy. Grade 1 or 2 
diarrhea occurred in 73% of patients on abemaciclib plus 
fulvestrant versus 24.2% of the patients on fulvestrant 
alone. Grade 3 diarrhea occurred in 13.4% of patients on 
the combination therapy versus 0.4% of those on fulvestrant 
alone. The majority of patients who experienced diarrhea did 
not require dose adjustments or discontinuation (70.1%), 
and only 2.9% of patients discontinued abemaciclib due to 
this side effect.
Thromboembolic events were the most frequently 
reported SAEs, occurring in 2% of the abemaciclib group 
patients versus 0.4% of the fulvestrant-alone group patients. 
None of these episodes resulted in death.38
In view of these results, on the September 28, 2017, the 
US Food and Drug Administration (FDA) granted approval 
for abemaciclib in combination with fulvestrant in patients 
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with HR+/HER2− advanced BC or mBC who progressed 
following endocrine therapy. On the same date, and on the 
basis of the MONARCH-1 trial results,39 abemaciclib also 
gained FDA approval as a single-agent therapy in patients 
with HR+/HER2− mBC who experienced disease progression 
following endocrine therapies and prior chemotherapy.
Furthermore, in September 2017, results of the 
MONARCH 3 trial of abemaciclib in combination with 
a nonsteroidal aromatase inhibitor (letrozole or anastro-
zole) were presented at the European Society for Medical 
Oncology (ESMO) 2017 Congress in Madrid40 and published 
immediately after.41
This randomized Phase III study compared abemaciclib 
or placebo in combination with a nonsteroidal aromatase 
inhibitor in postmenopausal patients with advanced 
HR+/HER2− BC who had no previous systemic therapies. 
The trial enrolled 493 patients. Abemaciclib was given at 
the standard dose of 150 mg twice daily (on a continuous 
schedule), while anastrozole and letrozole were given at 1 and 
2.5 mg daily, respectively. The primary objective of the trial 
was investigator-assessed PFS, and secondary objectives 
were evaluation of response and safety assessment.
Addition of abemaciclib to nonsteroidal aromatase 
inhibitors significantly prolonged PFS with an observed 
HR of 0.54 (95% CI: 0.41–0.72; p,0.000021), while the 
median PFS was not reached in the abemaciclib arm at 
interim analysis against 14.7 months in the placebo arm. 
Independent central review reached similar results (HR 0.51; 
95% CI: 0.36–0.72).
ORR was 48.2% (95% CI: 42.8%–53.6%) in the 
patients receiving abemaciclib versus 34.5% (95% CI: 
27.3%–41.8%) in the placebo-assigned patients (p,0.002). 
In patients with measurable disease, ORR was 59.2% (95% 
CI: 53.3%–65.1%) with abemaciclib and 43.8% (95% CI: 
35.3%–52.4%) with placebo (p,0.004). Clinical benefit was 
achieved by 78% (95% CI: 73.6%–82.5%) of the patients 
on abemaciclib and 71.5% (95% CI: 64.6%–78.4%) of the 
ones on placebo. Although all patients’ subgroups benefited 
from the addition of abemaciclib to endocrine therapy, it is 
worth noting that patients with better prognostic factors, such 
as prolonged treatment-free interval, bone-only secondary 
disease and no liver metastases, responded well to endo-
crine therapy alone. On the other hand, patients with shorter 
treatment-free interval or who presented liver metastases at 
baseline recorded higher benefit rate with abemaciclib.
The safety assessment demonstrated consistent results 
with previous abemaciclib trials: the most frequent all-grade 
adverse events in the investigational arm were diarrhea 
(81.3%), neutropenia (41.3%), fatigue (40.1%) and nausea 
(38.5%). The vast majority of diarrhea events were grade 1 
and 2 and occurred during the first cycle of therapy. Grade 3 
diarrhea was reported in 9.5% of cases. SAEs occurred in 
27.5% of patients treated with abemaciclib and in 14.9% of 
patients treated with placebo. The most common SAE was 
lung infection, occurring in 2.8% of patients on abemaciclib 
versus none of the patients on placebo.
Other ongoing Phase III studies are currently looking 
at the combination of abemaciclib and standard endocrine 
therapies in patients with early stage, high risk, node positive 
HR+/HER2− BC (NCT03155997, MONARCH E), as well 
as in postmenopausal patients with locoregionally recurrent 
or metastatic HR+/HER2− BC (NCT02763566, MONARCH 
plus; Table 2).
Abemaciclib is also being tested in other BC molecular 
subtypes, including HER2-positive BC and TNBC 
(NCT02675231, NCT03130439; Table 2).
Discussion
Numerous studies have highlighted the strong direct link 
existing between estrogen signaling pathway and the cell 
cycle.
Estrogen stimulation induces cell-cycle progression 
from G1 to S phase42 and increases cellular proliferation via 
upregulation of downstream cyclin D1 and CDK4/6, as well 
as C-MYC and cyclin E/CDK2.43 On the other hand, estrogen 
inhibition therapy, with aromatase inhibitors, tamoxifen 
and fulvestrant, induces cell-cycle arrest and consequently 
decreases cell viability.44,45
Moreover, Rb gene-negative breast tumors are resistant to 
tamoxifen in xenograft models and in the clinical setting,46,47 
proving that disruption of the Rb signaling pathway is indeed 
implicated in the cancer-inducing effects of estrogens.
Selective CDK4/6 inhibitors have shown impressive 
results in combination with antihormone therapies in advanced 
BC, leading to FDA approval of three compounds, palboci-
clib, ribociclib and most recently abemaciclib. The main rep-
resentative and the first of the anti-CDK4/6 family obtaining 
approval for first-line therapy in ER-positive advanced BC 
and mBC was palbociclib, in combination with letrozole and 
fulvestrant, respectively. In the PALOMA-1/TRIO-18 trial, 
the combination of palbociclib plus letrozole significantly 
increased the PFS from 7.5 months to 26.1 months (HR 0.37; 
p,0.001) in post-menopausal women with advanced BC.48 
Subsequently, palbociclib was tested in combination with 
fulvestrant in comparison to fulvestrant alone in patients 
with HR+/HER2− BC who progressed or relapsed after 
endocrine therapy (PALOMA 3 trial).49,50 The combination of 
palbociclib with fulvestrant granted longer PFS and a better 





quality of life in comparison to fulvestrant alone in these 
patients, irrespective of menopausal status. Median PFS was 
9.2 months with palbociclib–fulvestrant versus 3.8 months 
with placebo–fulvestrant (HR 0.42; p,0.001).
Ribociclib’s approval by the FDA for first-line treatment 
of postmenopausal women with HR+/HER2− advanced 
BC or mBC is based on the results from the Phase III 
MONALEESA-2 trial.51 The trial enrolled 668 postmeno-
pausal women with HR+/HER2− advanced BC or mBC 
who received no prior systemic therapy for their disease. 
The combination of ribociclib plus letrozole reduced the risk 
of progression (or death) by 44% over letrozole alone (with 
median PFS not reached in the combination arm [95% CI: 
19.3 months–not reached] versus 14.7 months [95% CI: 
13.0–16.5 months] in the letrozole alone arm; HR 0.556 
[95% CI: 0.429–0.720]; p,0.0001). The 24-month second 
interim analysis confirmed the superiority of the combination, 
with PFS rates of 54.7% for ribociclib plus letrozole versus 
35.9% for letrozole alone.52
Abemaciclib was the last CDK4/6 inhibitor approved by 
the FDA in combination with fulvestrant for the treatment of 
HR+/HER2− advanced BC or mBC, which has progressed 
with endocrine therapy. Notably, on the basis of the results of 
the MONARCH 1 trial,39 abemaciclib also obtained approval 
as a single-agent therapy in patients with HR+/HER2− mBC 
who experienced disease progression following endocrine 
therapy and prior chemotherapy.
While all three CDK4/6 inhibitors exhibit the same 
mechanism of action, inhibiting the ATP-binding domain of 
the kinases, there are some structural and biochemical dif-
ferences between the compounds (reviewed in Chen et al53), 
which account for differences in clinical activity.
While single-agent palbociclib and ribociclib showed 
only minimal antitumor activity,54–56 abemaciclib showed 
clinical benefit in heavily pretreated patient populations with 
metastatic HR+/HER2− BC who experienced progression 
with previous treatments37,39 and has thus been approved 
with this indication. Even though MONARCH 1 was a small 
Phase II study, the results indicate that abemaciclib can be 
used in endocrine-resistant metastatic tumors. In this patient 
group, the only remaining choice is chemotherapy, with very 
low response rates and median PFS of 3–4 months. On this 
Table 2 Current investigational clinical trials with abemaciclib (excluding MONARCH 1, 2 and 3)
Trial ID Phase Tumor type Population Therapies Primary outcome
NCT03155997/
MONARCH e
iii HR+/HeR2− BC High risk, node positive, 
early stage
Abemaciclib ± standard endocrine 
therapy
iDFS
NCT02779751 i HR+/HeR2− BC mBC Abemaciclib ± pembrolizumab SAes
NCT02747004 ii HR+/HeR2− BC Previously treated mBC Abemaciclib ± tamoxifen PFS
NCT02831530/
ABC-POP










NCT02308020 ii Brain metastases 
secondary to 
HR+/HeR2± BC
mBC Abemaciclib CR or PR: OiRR
NCT02675231/
monarcHeR
ii HR+/HeR2+ BC Locally advanced BC or 
mBC. Two previous lines 
of anti-HeR2 therapy
Abemaciclib + trastuzumab ± fulvestrant PFS
NCT02057133 i HR+/HeR2− BC mBC Abemaciclib + letrozole or anastrozole 
or tamoxifen or exemestane 
and/or everolimus or trastuzumab or 
LY3023414 or fulvestrant
SAes
NCT03099174 i HR+/HeR2− BC Advanced BC or mBC Abemaciclib + xentuzumab ± endocrine 
therapy
MTD, DLT, CR and PR as 
per ReCiST version 1.1
NCT02791334/PACT i HR+/HeR2− BC Advanced refractory BC Abemaciclib + LY3300054 DLT




Abemaciclib + LY3039478 MTD
NCT01655225 i HR+/HeR2− BC Locally advanced BC or 
mBC
Abemaciclib + LY3023414 + letrozole Recommended dose
NCT03130439 ii TNBC Rb-positive, triple 
negative metastatic BC
Abemaciclib ORR
Abbreviations: BC, breast cancer; iDFS, invasive disease-free survival; mBC, metastatic breast cancer; SAe, serious adverse event; PFS, progression-free survival; CR, 
complete response; PR, partial response; OiRR, objective intracranial response rate; MTD, maximum tolerated dose; DLT, dose-limiting toxicity; Rb, retinoblastoma; NSAi, 
non-steroidal aromatase inhibitor.
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trial, patients on abemaciclib, 90% of whom had visceral 
metastases and .50% had three or more sites of metastasis, 
showed a longer PFS (6 months) and a clinical benefit rate 
of 42.4%.
The reason behind the antitumor activity of abemaci-
clib in monotherapy is not completely understood. The 
administration schedule of abemaciclib is continuous, in 
contrast with that of both palbociclib and ribociclib, which 
is given consecutively for 21 days, followed by a 7 days 
break to control the dose-limiting myelosuppressive effect 
of these compounds. Preclinical studies in vitro and in vivo 
have shown that short-term inhibition of CDK4/6 in tumor 
cells causes a rebound effect with increased cellular pro-
liferation when the inhibition is withdrawn.23,57 This effect 
could explain the efficacy of continuously dosed abemaci-
clib as monotherapy in comparison to intermittently dosed 
palbociclib and ribociclib.
In addition, the safety profile of the three drugs is quite 
different. The dose-limiting toxicity (DLT) with palbociclib 
and ribociclib is neutropenia, while that with abemaciclib is 
fatigue. Grade 3 neutropenia is generally a relatively rare 
event with abemaciclib but occurs in up to 65% of the patients 
treated with palbociclib58 and 59.3% of the patients treated 
with ribociclib.51 On the other hand, gastrointestinal on-target 
effects, such as diarrhea, nausea and abdominal pain, are the 
most frequent toxicities reported with abemaciclib.
Abemaciclib is a 14 times more potent inhibitor of the 
CDK4/cyclin D1 complex24 than CDK6/cyclin D1/2/3. While 
activation of CDK4 is involved in breast tumorigenesis via 
cyclin D1 overexpression or genetic aberrations, CDK6 is 
important for hematopoiesis and differentiation of blood 
cells.59,60 Inhibition of CDK6 by palbociclib and ribociclib is 
responsible for the myelosuppression reported in the majority 
of patients using these drugs, which ultimately explains the 
intermittent regimen of administration.
Scientists are actively trying to elucidate the mechanisms 
behind non-hematological toxicities of abemaciclib. Besides 
CDK4 and CDK6, the ability, exclusive to abemaciclib, to 
target CDK9, a broadly expressed CDK regulating gene 
transcription, embryogenesis and cellular proliferation, may 
account for the specific toxicity profile and gastrointestinal 
adverse events.61
Furthermore, abemaciclib has shown a regular distribu-
tion across multiple systems, including the cerebrospinal 
fluid, with concentrations of drug comparable to those 
found in plasma.62 This finding has sparked interest for its 
use in treating primary and secondary brain tumors, and 
these indications are currently being investigated in clinical 
trials (NCT02308020, NCT02981940, NCT03220646, 
NCT02644460) with encouraging preliminary results.31 
Palbociclib, on the other hand, has provided contrasting 
results in this setting,33 and further clinical studies are ongo-
ing (NCT02774681, NCT02255461, NCT02255461).
Given the importance of PI3K signaling pathway’s 
genetic alterations in the pathogenesis of ER+/HER2− BC, 
abemaciclib is currently being investigated in doublet 
and triplet combinations with dual PI3K/mTOR inhibi-
tors plus or minus hormonal therapies (NCT02057133, 
NCT01655225).
Furthermore, in view of the recent pivotal report on the 
immune-boosting antitumor activity of abemaciclib,26 ran-
domized trials testing the combination of the anti-CDK4/6 
inhibitor with approved immunotherapies such as pembroli-
zumab (NCT02779751) and the novel anti PD-L1 antibody 
LY3300054 (PACT/NCT02791334) hold great promise.
Finally, following evidence that HER2 positive breast 
tumors resistant to trastuzumab are driven by cyclin D1 
overexpression,63 abemaciclib is currently being investigated 
in ER+/HER2+ advanced BC in combination with trastu-
zumab and fulvestrant in patients who progressed on previ-
ous anti-HER2 therapies (at least two lines) (monarcHER/
NCT02675231).
A parallel comparison of the three CDK4/6 inhibitors 
currently approved for therapy in advanced and metastatic 
HR+/HER2− BC could potentially help defining better 
therapeutic indications but is still lacking.
In addition, as acquired resistance to CDK4/6 inhibitors 
occurs, the question of whether a CDK4/6 can be substituted 
with another after progression is important and open. In fact, 
given the biological and clinical differences between the 
compounds, it may be hypothesized that the mechanisms 
of pharmacological resistance to one compound differ from 
the mechanisms of resistance to others. If this is the case, 
sequential therapy with CDK4/6 inhibitors could still be of 
benefit, perhaps in combination with other targeted therapies 
in selected patient subsets.
The identification of specific biomarkers could also 
help selecting subgroups of patients who are more likely to 
respond to one CDK4/6 inhibitor rather than the others.
HR+/HER2− advanced BC unmet 
needs
In the last 20 years, enormous progress in translational 
research has resulted in the development of numerous 
targeted therapies for the treatment of HR+/HER2− BC. 
Even in the presence of such armamentarium of new drugs, 





clinical results have been somehow disappointing, specifi-
cally in the metastatic setting, major setbacks being occur-
rence of pharmacological resistance and lack of reliable 
biomarkers of response to treatment.
Before the advent of CDK4/6 inhibitors, the only remain-
ing option for patients who progressed on endocrine thera-
pies was chemotherapy, with response rates in the order of 
10%–20% only.
Development of acquired resistance to endocrine and 
targeted therapies represents a major issue in the management 
of advanced and metastatic ER+ BC. Personalized medicine 
implies knowledge of the single tumor mutational land-
scape. While the advent of liquid biopsies and the analysis 
of secondary lesions via solid tumor biopsy will certainly 
facilitate identification of newly occurring mutations, sub-
clonal heterogeneity within both primary and secondary 
lesions may limit efficacy of targeted therapies.
To tackle this intrinsic heterogeneity, next-generation 
sequencing offers the possibility to characterize the whole 
genotype of the tumor, identifying the mutations cells are 
addicted to.
In this context, multiple reports have highlighted the 
importance of a combinatorial therapeutic approach to 
overcome occurrence of pharmacological resistance by 
targeting multiple signaling pathways at the same time,64–66 
and the design of clinical trials is, in fact, moving in this 
direction. On the other hand, even when sequential therapies 
are used, liquid biopsies would allow a “real-time” analysis 
of the tumor’s mutational landscape, with the possibility of 
adjusting therapies accordingly, as resistance occurs.67
Besides the phenomenon of acquired resistance, the lack 
of reliable predictive biomarkers for selection of the patients 
most likely to respond to targeted therapies represents another 
important limitation to applying precision medicine.
For instance, while amplification of cyclin D1 was initially 
evaluated as a biomarker for stratification of patients treated 
with CDK4/6 inhibitors, it failed to show any meaningful 
correlation with response in clinical trials.48
CDK4/6 inhibitors require functional Rb protein to exert 
their antitumor activity. Loss of Rb is a marker of resistance 
to treatment, but the majority of HR+ BCs are Rb proficient.11 
Acquired pharmacological resistance to palbociclib occurs via 
loss of Rb and amplification of cyclin E1,68 and the combina-
tion of a CDK4/6 inhibitor and a CDK2 inhibitor may repre-
sent a strategy to overcome resistance to CDK4/6 inhibitors.
Conclusion
The approval of abemaciclib adds another option to the 
armamentarium of effective CDK4/6 inhibitors currently 
available. The latest agent, such as palbociclib and ribociclib, 
responds to a pressing unmet need of patients with hormone 
receptor positive, HER2-negative mBC patients who have 
progressed on endocrine therapies, offering a more effective 
option than chemotherapy. More specifically than the other 
CDK4/6 inhibitors, abemaciclib seems to obtain the best 
results in heavily pretreated patients with visceral disease 
and worse prognosis.
Furthermore, the ability to cross the blood–brain barrier 
and the potential synergism between abemaciclib and targeted 
immunotherapies represent interesting aspects and offer pos-
sibilities for more effective multiple combination therapies.
Important questions about the correct use of CDK4/6 
inhibitors, potential biomarkers of response and mecha-
nisms of acquired resistance are still open and may be 
addressed in the future by specifically designed randomized 
clinical trials.
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